Table 3

Effect of surveillance diagnosing endoscopy on mortality risk of patients with Barrett's oesophagus and newly diagnosed oesophageal adenocarcinoma (EAC)

HR95% CI
BE surveillance diagnosing EGD vs non-surveillance
All EAC cases (n=207/424; 81/209 surveillance and 126/215 non-surveillance)
 Unadjusted0.520.39 to 0.69
 Adjusted* (without stage or treatment)0.490.37 to 0.66
 Adjusted (including stage)0.760.55 to 1.06
 Adjusted (including stage and treatment)0.730.52 to 1.01
EAC-related mortality (n=187/424; 71/209 surveillance and 116/215 non-surveillance)
 Unadjusted0.500.37 to 0.67
 Adjusted* (without stage or treatment)0.470.35 to 0.64
 Adjusted (including stage)0.750.53 to 1.05
 Adjusted (including stage and treatment)0.720.51 to 1.01
  • *Adjusted for year of EAC diagnosis, age, race, propensity of EGD, comorbidity score, total number of VA visit and GI clinic visit.

  • EGD, oesophagogastroduodenoscopy; VA, Veteran Affairs.